



# Akari Therapeutics

A Multi-Faceted Biotech Company  
Q4-2024

# Forward-Looking Statements

This communication relates to the proposed transaction pursuant to the terms of the Merger Agreement, by and among Akari, Pegasus Merger Sub, Inc., and Peak Bio. This communication includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), about the proposed transaction between Peak Bio and Akari and the operations of the combined company that involve risks and uncertainties relating to future events and the future performance of Akari and Peak Bio. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the business combination and related matters, including, but not limited to, satisfaction of closing conditions to the proposed transaction, prospective performance and opportunities with respect to Akari or Peak Bio, post-closing operations and the outlook for the companies’ businesses; Akari’s, Peak Bio’s or the combined company’s targets, plans, objectives or goals for future operations, including those related to Akari’s and Peak Bio’s product candidates, research and development, product candidate introductions and product candidate approvals as well as cooperation in relation thereto; projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; future economic performance, future actions and outcome of contingencies such as legal proceedings; and the assumptions underlying or relating to such statements. These statements are based on Akari’s and Peak Bio’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing for completion of the proposed transaction; uncertainties as to Peak Bio’s and/or Akari’s ability to obtain the approval of Akari’s shareholders or Peak Bio’s stockholders required to consummate the proposed transaction; the possibility that competing offers will be made by third parties; the occurrence of events that may give rise to a right of one or both of Akari and Peak Bio to terminate the merger agreement; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived on a timely basis or at all, including the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of consents or regulatory approvals or actions, if any; the possibility that the proposed transaction may not be completed in the time frame expected by Akari and Peak Bio, or at all; the risk that Akari and Peak Bio may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the effects of the proposed transaction on relationships with Akari’s or Peak Bio’s employees, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; significant or unexpected costs, charges or expenses resulting from the proposed transaction; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business after the consummation of the proposed transaction; potential negative effects related to this announcement or the consummation of the proposed transaction on the market price of Akari’s American Depositary Shares or Peak Bio’s common stock and/or Akari’s or Peak Bio’s operating or financial results; uncertainties as to the long-term value of Akari’s American Depositary Shares (and the ordinary shares represented thereby), including the dilution caused by Akari’s issuance of additional American Depositary Shares (and the ordinary shares represented thereby) in connection with the proposed transaction; unknown liabilities related to Akari or Peak Bio; the nature, cost and outcome of any litigation and other legal proceedings involving Akari, Peak Bio or their respective directors, including any legal proceedings related to the proposed transaction; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of Akari’s or Peak Bio’s programs or product candidates; risks related to any loss of Akari’s or Peak Bio’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for Akari or Peak Bio’s product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by Akari, Peak Bio and/or their respective collaborators or licensees; the extent to which the results from the research and development programs conducted by Akari, Peak Bio, and/or their respective collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of Akari’s or Peak Bio’s product candidates, and the impact of studies (whether conducted by Akari, Peak Bio or others and whether mandated or voluntary) on any of the foregoing; unexpected breaches or terminations with respect to Akari’s or Peak Bio’s material contracts or arrangements; risks related to competition for Akari’s or Peak Bio’s product candidates; Akari’s or Peak Bio’s ability to successfully develop or commercialize Akari’s or Peak Bio’s product candidates; Akari’s, Peak Bio’s, and their collaborators’ abilities to continue to conduct current and future developmental, preclinical and clinical programs; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of Akari’s or Peak Bio’s product candidates; unexpected increase in costs and expenses with respect to the potential transaction or Akari’s or Peak Bio’s business or operations; and risks and uncertainties related to epidemics, pandemics or other public health crises and their impact on Akari’s and Peak Bio’s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials, strategy, goals and anticipated milestones. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the proposed transaction or any other transaction described above will in fact be consummated in the manner described or at all. A more complete description of these and other material risks can be found in Akari’s and Peak Bio’s respective filings with the U.S. Securities and Exchange Commission (the “SEC”), including each of their Annual Reports on 10-K, for the year ended December 31, 2023 and 2022, respectively, subsequent periodic reports, and other documents that may be filed from time to time with the SEC. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the joint proxy statement/prospectus that are included in the registration statement on Form S-4 that was filed with the SEC on September 13, 2024 in connection with the proposed transaction. Such joint proxy statement/prospectus will be mailed or otherwise disseminated to Akari’s shareholders and Peak Bio’s stockholders when it becomes available. Any forward-looking statements speak only as of the date of this communication and are made based on the current beliefs and judgments of Akari’s and Peak Bio’s management, and the reader is cautioned not to rely on any forward-looking statements made by Akari or Peak Bio. Unless required by law, neither Akari nor Peak Bio is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.

# Additional Disclosures

## **Additional Information and Where to Find It**

The Registration Statement on Form S-4 includes a prospectus of Akari and a joint proxy statement of Akari and Peak Bio. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE REGISTRATION STATEMENT ON FORM S-4, JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN, IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.

You may obtain a free copy of the Registration Statement on Form S-4, joint proxy statement/prospectus and other relevant documents that are on file with the SEC for free at the SEC's website at [www.sec.gov](http://www.sec.gov). Copies of the documents filed with the SEC by Akari are available free of charge on Akari's website at <http://investor.akarix.com/> or by contacting Akari's Investor Relations Department at <http://investor.akarix.com/investor-resources/contact-us>. Copies of the documents filed with the SEC by Peak Bio are available free of charge on Peak Bio's website at <https://peak-bio.com/investors> or by contacting Peak Bio's Investor Relations Department at <https://peak-bio.com/contact>.

## **Participants in the Solicitation**

Akari and Peak Bio and certain of their respective directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from the securityholders of Akari and Peak Bio in favor of the Business Combination. Securityholders of Akari and Peak Bio and other interested persons may obtain more information regarding the names and interests of Akari and Peak Bio directors and officers in the Business Combination in Akari and Peak Bio filings with the SEC, including in the definitive proxy statement/prospectus, included in the Registration Statement. These documents can be obtained free of charge from the sources indicated above.

## **Disclaimer**

This confidential presentation ("Presentation") is for informational purposes only and is being provided to interested parties solely in their capacities as potential investors and is provided solely for the purpose of allowing interested parties to make their own evaluation with respect to a potential private offering of securities (the "Purpose") of Akari Therapeutics Plc. (the "Company"). By accepting this Presentation, you acknowledge and agree that all of the information contained herein is confidential, that you will distribute, disclose, and use such information only for such Purpose and that you shall not distribute, disclose or use such information in any way detrimental to the Company. Any reproduction or distribution of this Presentation, in whole or in part, or the disclosure of its contents, without the prior consent of the Company, is prohibited. You agree to return or destroy all copies of this Presentation or portions thereof in your possession following the request for the return or destruction of such copies. The information contained herein does not purport to be complete or comprehensive and neither the Company nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein and the Purpose, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision.

## **Private Placement**

This Presentation and any oral statements made in connection with this Presentation shall neither constitute an offer to sell nor the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdictions. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation.

ANY SECURITIES TO BE OFFERED IN ANY TRANSACTION CONTEMPLATED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY APPLICABLE STATE OR FOREIGN SECURITIES LAW. ANY SECURITIES TO BE OFFERED IN ANY TRANSACTION CONTEMPLATED HEREBY HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC"), ANY STATE SECURITIES COMMISSION OR OTHER UNITED STATES OR FOREIGN REGULATORY AUTHORITY, NOR HAVE ANY OF THESE AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR DETERMINED THAT THIS PRESENTATION IS ACCURATE OR COMPLETE. ANY SECURITIES TO BE OFFERED WILL BE OFFERED AND SOLD SOLELY IN RELIANCE ON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND RULES AND REGULATIONS PROMULGATED THEREUNDER. THIS DOCUMENT DOES NOT CONSTITUTE, OR FORM A PART OF, AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY IN ANY STATE OR OTHER JURISDICTION TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION IN SUCH STATE OR JURISDICTION.

# Merger of Akari Therapeutics and Peak Bio Creates a Multi-Faceted Biotech Company



## Diverse pipeline provides potential for multiple shots on goal

- *TROP2 PH1 ADC*: Antibody-drug conjugate (ADC) – pre-clinical program for solid tumors
- *PAS-nomacopan*: Geographic atrophy (GA) – pre-clinical program for ophthalmology
- *PHP 303 and nomacopan*: Multiple indications – phase 3-ready program offers near-term BD potential



## Lead assets in areas of high unmet medical need provide multi-billion-dollar market opportunities in oncology and geographic atrophy

- Combines high unmet needs and large markets in oncology and ophthalmology
- Solid tumors represent ~90% of all tumors
- It is estimated that >1 million people in the USA have geographic atrophy



## Lead programs leverage unique mechanisms of action backed by robust preclinical data sets that point to potential clinical benefit

- ADC franchise includes a wide array of cleavable and non-cleavable linkers as well as a payload that modulates the spliceosome
- PAS-nomacopan is a long-acting bispecific inhibitor of C5 and LBT4 in development for geographic atrophy
- Protected by broad intellectual property coverage



## Merger brings end-to-end capabilities with a combined management team and board that brings proven track record of value creation in life sciences

- Merger results in significant operational efficiency for the company
- Funds to finance multiple value-creating near-term milestones

# Prioritized Pipeline Focuses on Areas of High Unmet Medical Need

	Program	Indication	Discovery	Preclinical	Phase I	Phase II	Phase III	Strategy
Active programs	<b>TROP2 PH1 ADC</b> <i>ADC with novel payload</i>	<b>Solid Tumors</b>						<ul style="list-style-type: none"> <li>Ongoing pre-clinical activities</li> <li>Pursue licensing/strategic partnership in 2025</li> </ul>
	<b>PAS-Nomacopan</b> <i>Long-acting complement C5 and leukotriene B4 inhibitor for eye</i>	<b>GA</b>						<ul style="list-style-type: none"> <li>File IND in 2025</li> <li>Initiate Phase I study in 2025</li> </ul>
Programs for partnership	<b>PHP-303</b> <i>Neutrophil elastase inhibitor</i>	<b>AATD</b>						<ul style="list-style-type: none"> <li>Preclinical activities paused</li> <li>Pursue licensing/strategic partnership in 2025</li> </ul>
		<b>ARDS</b>						<ul style="list-style-type: none"> <li>Clinical activities paused</li> <li>Pursue licensing/strategic partnership in 2025</li> </ul>
	<b>Nomacopan</b> <i>Complement C5 and leukotriene B4 inhibitor for systemic conditions</i>	<b>HSCT-TMA</b>						<ul style="list-style-type: none"> <li>Preclinical/clinical activities paused</li> <li>Pursue licensing/strategic partnership</li> </ul>
<b>BP, PNH</b>								
<b>Trauma</b>								

# Led by a Management Team With Extensive Experience in Life Sciences

**Samir Patel, M.D.**  
*Interim President & CEO*  
 Strategic leader with extensive operational, financial and commercial experience



**Wendy F. DiCicco**  
*Interim CFO*  
 Strategic financial leader with extensive background in life sciences



**Miles Nunn**  
*Chief Scientific Officer*  
 Inventor of nomacopan and innovative scientist and discoverer



**Hoyoung Huh, M.D., Ph.D.**  
*Chairman*  
 Visionary investor/entrepreneur involved in start-up, management, and boards of numerous healthcare companies



# *Antibody Drug Conjugate (ADC)*

- *Innovative platform*

# Our ADCs Leverage Novel Linker Technology and Mechanism of Action

## Traditional ADC Approach

### *Targeted killing of cancer cells by specific antibody coupled to a cytotoxic (payload)*

- Over 70% of payloads in currently approved ADCs target tubulin or DNA\*
- Industry standard payloads can have off-target effects and toxicities (e.g. ocular, hematologic, peripheral neuropathy) that may limit their use
- Majority of current payloads are substrates of drug efflux transporters called multi-drug resistance transporters permitting development of drug resistance in some cancer patients

*\*Topoisomerase and microtubule inhibitor payloads inhibit DNA replication and cancer cell division and pyrrolobenzodiazepines (PBD) payloads cross-link DNA*

## How is our ADC approach different?


### *Highly targeted killing of cancer cells and more potent engagement of immune system to kill cancer*

- Differentiated **novel payloads** targeting proper **splicing of introns** (PH-1), **DNA mismatch repair** (PH-5) and **immune system mediated killing** of co-opted tumor cells/pro-tumor cells (PH-6)
- PH1 **enhances tumoricidal activity** beyond immediate cytotoxicity by **creating neoepitopes**, providing a 1-2 punch of initial cytotoxicity followed by prolonged immune-mediated cell death
- PH1 induced immune memory (B and T cells) can potentially re-engage when treated cancers recur countering resistance due to loss of target expression.
- PH1 has differentiated toxicity, relative to industry standard payloads
- PH1 (and potentially PH5 and PH6) payload is a poor substrate for MDR transporters that may decrease risk of patient developing drug resistance



# ADC Market is Projected to Reach Over \$22B by 2030

## Approved Therapies Projected Revenue: \$22B+ by 2030<sup>1</sup>



Note: Does not include Mylotarg or Lumoxiti as not broken out in consensus estimates; Padcev's ex-US portion/ Enhertu consensus estimates based off Astellas/ Daiichi's calendarization;  
 Note: Kadcyla/Polivy consensus in CHF, Blenrep in GBP; Padcev ex-US portion consensus portion in JPY; Converted to USD using 12/31/20 conversion rate

- ADC market projected to grow > 20% over the next few years
- Global Trop2 market expected to surpass \$4 billion by 2026<sup>1</sup>
- Key Trop2 antibody market competitors include Daiichi Sankyo/AstraZeneca and Immunomedics/Gilead

## Strong Deal Flow Even for Pre-Clinical ADC Assets\*

Partners	Asset	Target	Deal Type	Date	Phase	Deal Value
Multitude Therapeutics and Adcendo	ADCE-T02 ADC	Tissue Factor	Licensing	Aug-24	Pre-clinical	Upfront not revealed; Potentially >1b in milestones, Single-digit to low double-digit tiered royalties
Kelun-Biotech and Merck	SKB571	Undisclosed	Licensing	Aug-24	Pre-clinical	\$35m upfront, \$37.5m on option exercise, undisclosed sales milestones and tiered royalties
Aarvik Therapeutics and ArriVent BioPharma	Undisclosed ADC, novel platform	Unknown	Strategic Collaboration & Licensing	Aug-24	Pre-clinical	Upfront and opt-in undisclosed. Research funding, Option fees, and milestones ~\$100m plus royalties
Biocytogen & Sotio and Ideaya Biosciences	Bispecific ADC	B7H3 x PTK7	Licensing	Jul-24	Pre-clinical	\$6.5m Opt-in, \$400m in milestones including \$100m tied to development and regulatory events
Mabcare Therapeutics and DayOne	DAY301/ MTX-13	PTK-7	Licensing	Jun-24	Pre-clinical (IND enabled)	\$55M upfront; Up to \$1.2B exclusive commercial rights
Medilink and BioNtech	TMALIN ADC platform	Undisclosed	Licensing	May-24	Pre-clinical	\$25M upfront; Up to \$1.8B in milestones
Caris and Merck KGaA	Targets	Undisclosed	Licensing	Apr-24	Pre-clinical	Up to \$1.4B in milestones
Sutro Biopharma and Ipsen	STRO-003	ROR1	Licensing	Apr-24	Pre-clinical	\$90M upfront; Phase 1 by Ipsen \$900M in milestones
AstraZeneca and LaNova	LM-305	GPRC5D	Licensing	May-23	Pre-clinical (IND approved)	\$55M upfront; \$545M milestones
BMS and Tubulis	Tubutecan payloads and p5 conjugation platform	Undisclosed	Collaboration	Apr-23	Pre-clinical	\$22.75M upfront; \$1B milestones
Merck and Kelun-Biotech	Undisclosed	Undisclosed	Licensing	Jul-22	Pre-clinical	\$35M upfront; \$901M milestones
ImmunoGen and Lilly	Camptothecins	Undisclosed	Licensing	Feb-22	Pre-clinical	\$13M+\$32.5M upfront; \$1.7B milestones
Mersana and Janssen	Discovery of new ADCs	Up to 3 targets	Collaboration	Feb-22	Pre-clinical	\$40M upfront; \$1B milestones

\* Does not reflect all preclinical ADC deals. Deals with undisclosed deal values left out. For e.g., Sony Corp. and Astellas (May-23), Ajinomoto and Exelixis (Jan-23), Sanofi and Seagen (Mar-22) etc.

# *Novel Payload Platforms*

- *Most advanced payload PH1 targets the spliceosome*
- *Linker toolkit for PH1 – leverages both cleavable and non-cleavable mechanisms*
- *Novel mechanisms of action*
  - *Generation of neoepitopes*
  - *Secondary immune mechanism of action*
  - *Selected for lack of binding to MDR transporters*

# We Have Developed a Diverse Toxin Linker Toolkit for PH1 ADCs


Our Library Permits Selection of Optimal Linker for PH1 ADC Cytotoxic Potency\*

Linkers	Non-Cleavable	Cleavable
Lys	<div data-bbox="377 475 583 578">L2</div> <p><b>A13d2ThL2</b> non-cleavable (Lys)</p> <div data-bbox="377 682 583 756">L22 (PH1)</div> <p><b>A13d2ThL22</b> non-cleavable (Lys)</p>	<div data-bbox="1340 489 1551 558">L91</div> <p><b>A13d2ThL91</b> Val - Cit cleavable linker (Lys)</p> <div data-bbox="1340 625 1551 694">L92</div> <p><b>A13d2ThL92</b> Val - Ala cleavable linker (Lys)</p> <div data-bbox="1340 768 1551 836">L94</div> <p><b>A13d2ThL94</b> Val - Ala cleavable linker (Lys)</p>
Cys	<div data-bbox="377 925 583 993">L18</div> <p><b>A13d2ThL18</b> non-cleavable linker (Cys)</p>	<div data-bbox="1340 939 1551 1008">L11</div> <p><b>A13d2ThL11</b> SPDP-cleavable linker (Cys)</p>

\*Tested *in vivo*.

# PH1 Payload Is a Spliceosome Modulator With a Multi-Pronged Anti-Tumor Activity

## PH1 ADC



By targeting normal splicing and tumor specific splicing of introns PH1:

1. **Disrupts tumor specific alternative splicing**, a fundamental process for tumor transformation and growth. Resulting mRNA decay deprives cancer cells of essential proteins.
2. **Causes accumulation of mis-spliced proteins** (majority of transcripts) inducing cell death by unfolded protein response (UPR) and endoplasmic reticulum stress.
3. **Generates neoantigens** (rare transcripts) that can stimulate the immune response.

1. Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment Martínez-Montiel N et al (2016) <http://dx.doi.org/10.1155/2016/3681094>;



2. Altered RNA Processing in Cancer Pathogenesis and Therapy Obeng et al (2019) <https://doi.org/10.1158/2159-8290.CD-19-0399>

# PH1 Greatly Elevates Abundance and Diversity of Mis-Spliced RNA

Average (n=4 wells) expression of spliced RNA transcripts showing effect of DM4 and PH1 payloads compared to control

1 – 2 punch of PH1:

- (1) Cytotoxicity by disrupting splicing
- (2) Increased neoepitope formation



● Mis-spliced RNAs including some potentially contributing to neoepitopes

● Unchanged spliced RNAs/mRNAs

● Mis-spliced RNAs that are known substrates for nonsense mediated mRNA decay (NMD)

- Each dot represents a specific RNA derived by splicing
- PH1 treatment markedly increases both number and diversity of mis-spliced RNAs that may be eliminated by NMD (3x DM4) or contribute to neoepitopes (9x DM4)


# PH1 May Prevent Development of MDR-Mediated Resistance

## PH1 Is a Poor Substrate for MDR Transporters


### Method:

Normal MES-SA cells & MES-SA cells selected for overexpression of MDR transporter 1/2 exposed *in vitro* to PH1 or anti-tubulin payload MMAE (monomethyl auristatin E), in presence or absence of MDR 1/2 inhibitor elacridar

- MES-SA uterine sarcoma cell line
- MES-SA cells expressing high levels of MDR transporter 1 and 2 which can pump toxins out of cells
- ▲ MES-SA cells with high MDR expression + MDR inhibitor elacridar



PH1 potency unaffected by overexpression of multidrug resistance (MDR) transporters



200X higher MMAE concentration required to kill cells overexpressing MDRs; inhibition of MDR 1/2 by elacridar restores MMAE potency


# *Trop2 PH1 ADC*

- *Proprietary Trop2 mAb (M2.1)*
- *Optimization of payload linker*
- *Trophoblast cell surface antigen 2 (Trop2) PH1 ADC*
- *Low off-target activity*
- *Differentiated efficacy in xenograft model*
- *Potential increased efficacy as combination therapy*
- *Differentiated safety in NHP model*

# Our Trop2 mAb Demonstrates High Affinity for TROP2 Comparable to Trodelvy®

## Daiichi mAb (Datopotamab DXd)


Loading Sample ID: DA; Sample ID: Trop-2; KD (M): 2.463E-08 - by Conc. (nM)



$K_d$ : 24.6nM

## Immunomedics mAb (Trodelvy®)


Loading Sample ID: IM; Sample ID: Trop-2; KD (M): 2.497E-09 - by Conc. (nM)



$K_d$ : 2.50nM

## PEAK Trop2 mAb (M2.1)

Loading Sample ID: 8A; Sample ID: Trop-2; KD (M): 8.971E-09 - by Conc. (nM)




$K_d$ : 8.97nM

- M2.1 variant has high binding affinity akin to that of Immunomedics mAb
- The Daiichi mAb (TINA) has a very distinct profile in comparison to the Immunomedics mAb (hRS7)



# Trop2-PH1 ADC Linker Screen for Optimal Efficacy: Lysine Conjugates With Non-Cleavable Linker Have the Highest Potency


hRS7 IgG1k monoclonal antibody from Trodelvy® and was conjugated to PH-1 suite of linker toxins L2, L22 (PH1), L18 and L92 at the indicated drug antibody ratios (DAR)



# Clinically Validated Trop2 Target as First Named PH1 Program


## Trop2 PH1 ADC-potent *in-vitro* activity

Normal human fibroblasts




No cytotoxicity against normal human fibroblasts as observed in FIC (Attributed to superior linker stability)

NCI-N87 gastric Trop2<sup>high</sup>




In gastric cancer, superior cytotoxicity at lower DAR than first-in-class (FIC) ADC therapy Trodelvy®

BxPC3 pancreatic Trop2<sup>high</sup>



In pancreatic cancer cells, comparable cytotoxicity at lower DAR than FIC

RT112/84 bladder Trop2<sup>heterogenous</sup>



In bladder cancer, comparable cytotoxicity at lower DAR than FIC

- Data (top R figure) shows superior specificity of Trop2 PH1 to cancer cells (possibly due to linker stability) compared to Trodelvy® which exhibits significant toxicity to normal fibroblasts (top L figure)
- Trop2 PH1 equal or more potent than Trodelvy® in NCI-N87 gastric cancer
- Trop2 PH1 equipotent compared to bystander-enabled Trodelvy® in Trop2<sup>high</sup> BxPC3 pancreatic cancer and in RT112/84 bladder cancer with heterogenous Trop2 expression (bottom R)
- Additional data on Trop2 PH1 killing of a wide range of tumor cell types *in vitro* in backup


**SUPPORTS POTENTIAL UTILITY OF Trop2 PH1 ADC IN A WIDE RANGE OF SOLID TUMORS**

# Payload Superiority of PH1 Over SN-38 on IMMU-132 Antibody Anti-Trop2-PH1 ADC-Induced Tumor Regression Is Dose Dependent

## Method:

- Human NCI-N87 cell line used to model human gastric adenocarcinoma as subcutaneous xenografts in athymic BALB/c mice lacking an adaptive immune system
- In therapeutic mode, tumors allowed to grow, and mice randomized so average tumor size 200 mm<sup>3</sup> on Day 1
- Mice dosed on Days 1 and 8
- Tumor volumes measured throughout the study

PH1 coupled to anti-Trop2 antibody exhibits significantly higher rate of tumor regression at a lower dose and DAR than SN38 coupled to anti-Trop2




## ADCs used:

**Anti-RSV PH1** = anti-respiratory syncytial virus isotype matched mAb conjugated to PH1  
**NEGATIVE CONTROL ADC** (no target on cell)

**IMMU-132** = sacituzumab govitecan-hziy (Immunomedics) anti Trop 2 mAb hRS7 conjugated to SN-38 (an active metabolite of irinotecan), a topoisomerase I inhibitor. Derived in house, but expected similar to Trodelvy®  
**FIRST-IN-CLASS CONTROL**

**hRS7 PH1** = antitrophoblast cell-surface antigen 2 (Trop-2) monoclonal antibody conjugated to PH1

# Trop2 PH1 ADC in Gastric Cancer Model: Tumor Regression At Lower Drug-Antibody Ratio (DAR) and Lower Dose Than Trodelvy®



## Method

- NCI-N87 cell xenograft model
- Mice dosed IV with ADC or vehicle on day 1 and day 8 post-randomization

- Trop2-PH1 exhibits dose dependency and higher rate of tumor regression and long-term stabilization than Trodelvy® (Trop2-SN38 ADC)
- Prolonged duration of action of Trop2-PH1 likely due to induction of innate immune response


At DAR4, TR in 50% of treated mice over a period of ~5 months

At DAR2, stable disease in 50% of treated mice over ~5 months

Group	TGI ± Std Err (day 20)	p Value vs Trop2 PH1 (DAR4) (day 20)	TGI ± Std Err (Day 41)	p Value vs Trop2 PH1 (DAR4) (day 41)
Trop2 PH1 (DAR 4)	87.7 ± 1.0		90.3 ± 1.8	
Trop2 PH1 (DAR 2)	80.5 ± 1.8	0.00014	78.5 ± 3.2	0.0014
Trodelvy (DAR 7.6)	79.0 ± 2.1	0.000028	83.3 ± 2.4	0.035


# Trop2 PH1 ADC Combines With Standard-Of-Care Immunotherapy and Prolongs Overall Survival in Syngeneic Urothelial Cancer Model in Mice With Intact Immune System

*Superior anti-tumor efficacy for Trop2 PH1 ADC plus SOC combination therapy*



*Trop2 PH1 ADC single agent efficacy is comparable to SOC*

*Improved OS for Trop2 PH1 ADC plus SOC combination therapy*



Note: Patent pending so exact model, I/O drug and dosing not disclosed

*Trop2 PH1 ADC single agent extends OS comparable to SOC*

Efficacy against mouse bladder syngeneic cancer tumor model (urothelial) expressing human Trop2 protein

# Trop2 PH1 ADC Safety By Intravenous Administration: Proof-of-Concept Demonstrated Differentiated Safety Profile in NHP

- Doses examined 2mg/kg, 6mg/kg and 18mg/kg IV Q3W x 3 repeat doses at DAR2 and DAR4
  - 3 animals in each group, 2 sacrificed at end of dosing and 1 after further 3-week recovery period
- Maximum tolerated dose (MTD) 6 mg/kg caused mild-minimal or transient observations that reset to baseline within 2 weeks
  - Mild and reversible elevations in liver enzymes
  - Mild and reversible thrombocytopenia
  - Skin rash
- Differentiated safety profile from other competitor ADCs in clinic
  - No evidence of reported Trop2 related ADC toxicities such as neutropenia, peripheral neuropathy, stomatitis, or interstitial lung disease (ILD)
  - No nausea, vomiting or diarrhea at MTD
- Toxicity profile may allow combination with checkpoint inhibitors
  - No evidence of lung complications such as pneumonitis
  - No colitis or hypothyroidism

# Summary of Trop2 PH1 ADC Characteristics

- **Nanomolar potency** against multiple types of solid tumors with potential **utility against wide range of cancers** either alone or in combination with I/O therapy
- **Superior specificity** to cancer cells (possibly due to linker stability) and unique **ability to generate neoepitopes**
- PH1 **payload efficacy is dose and DAR dependent** and appears to **induce innate and adaptive immunity** and anti-tumor immune memory evidenced by prolonged overall survival of mice after acute dosing
- **Promising safety in non-human primate** tox study with differentiated toxicity profile that may favor use with specific I/O therapies
- Trop2 mAb **ready for GMP manufacturing** development - lead selected, expressed and purified 30L scale and stability profile characterized

# *PASylated<sup>®</sup>-Nomacopan*

## *Geographic Atrophy (GA)*

- *Bispecific inhibitor of C5 and LTB4*
- *Potential for 3 – 4 injections/year*
- *Potential for better safety than approved complement only drugs*


**Nomacopan is the parent asset that was evaluated in two phase 3 clinical trials in hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and in paroxysmal nocturnal hemoglobinuria (PNH), while long-acting PASylated<sup>®</sup>-nomacopan is in the final stage of pre-clinical development as a potential treatment for geographic atrophy (GA)**



# Currently Approved Treatments in GA

- GA is an advanced form of dry age-related macular degeneration (dAMD) with growth of atrophic lesions causing loss of photoreceptors and ultimately legal blindness in a median of c.6 years<sup>1</sup>
- Complement has an important role in driving the pathology<sup>2</sup> and lesion growth (see Figure on right) as demonstrated by the first recently approved (2023) treatments for GA which are both complement inhibitors: Izervay™/Astellas, anti-C5 Syfovre™ /Apellis, anti-C3

**Both approved drugs have been shown to decrease the growth rate of lesions**




## **Non-central atrophy**

Some loss of peripheral, low light vision


## **Growth of non-central atrophy**

Loss of peripheral, low light vision



## **Starting to affect fovea**

Loss of peripheral, low light vision; patches of lost central vision



## **Severe central atrophy**

Loss of central vision leading to blindness

NOTE: Figure adapted from Fig 2 in reference 2 below


# PAS-Nomacopan Is Designed to Address Unmet Needs in GA Identified by Retinal Specialists

**MIZUHO** Mizuho Securities USA LLC

U.S. Equity Research

November 1, 2023

## Results from Proprietary Survey of Retinal Specialists



NOTE:  $\leq 3\%$  of retinal specialists highlighted: Dosing convenience for physician; Physician practice economics; price/reimbursement; and compliance

## PAS-nomacopan's target product profile



Inhibition of two proinflammatory pathways in eye has potential to improve efficacy over complement only inhibitors




LTB4 inhibition can prevent VEGF-A overexpression<sup>1,2</sup>, which may drive new onset CNV caused<sup>3,4</sup> by the approved drugs



PASylation<sup>®</sup> technology enables potential for only 3 to 4 intravitreal (IVT) injections each year vs 6 – 12 for approved therapies<sup>5,6</sup>

# What is PASylated® (PAS)-Nomacopan?




**PAS-nomacopan is a long-acting bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) derived from nomacopan by fusion of a 600 amino acid proline-alanine-serine (PAS) repeat**

- PASylation<sup>1</sup> is a biological alternative to expensive chemical addition of synthetic polymers such as polyethylene glycol (PEG). Like PEG, PAS greatly increases the hydrodynamic radius of proteins.
- PAS-nomacopan has a hydrodynamic radius of 9.3nm and nomacopan 2.5nm.<sup>2</sup> Hydrodynamic radius is normally strongly associated with residency time in the eye.<sup>3</sup>
- PAS-nomacopan has full biochemical activity versus C5 ( $K_D$  25pM)<sup>4</sup> and LTB4 ( $K_D$  255pM)<sup>2</sup> with potency equivalent to nomacopan.
- PAS-nomacopan is expressed in a proprietary strain of bacteria and needs no post purification chemical coupling as it is manufactured with PAS fused in frame to the N-terminal of nomacopan (see figure).

# PAS-Nomacopan Inhibits Two Pathways That Can Cause Damaging Inflammation, While Preserving Beneficial Immune Functions

## Complement (C5) inhibition

Complement system activated by IgG, foreign carbohydrate, damage associated molecular patterns (DAMPs), and cell surfaces not recognized as 'self'




## Overlapping proinflammatory effects caused by complement & LTB4

- Granulocyte activation**
- Phagocyte activation**
- Induction of cytokines**
- Induction of chemokines**
- Procoagulant effects**
- Cell lysis / Activation**
- Modulation B and T cells**

**PAS-nomacopan**



## Leukotriene (LTB4) inhibition

Eicosanoid system activated by Fc receptor engagement, cytokines, and terminal complement products



Both complement and leukotriene pathways are active within the eye

# Development of Long-Acting PAS-Nomacopan: Current Data and Potential Final IND-Enabling Steps



- **Data from non-clinical studies supports potential dose interval of 3 months or longer:**
  - Half-life rabbit vitreous 7.4 – 8.4 days with good bioavailability in other eye tissues (retina and RPE/choroid). Positive relationship between dose (1 mg or 3 mg/eye) and drug concentration in vitreous was observed (see Figures L).
  - Drug tolerated in rabbit non-GLP studies with some evidence of immune response akin to other biological drugs (such as anti-VEGFs) injected to eye.
- **GMP drug substance (DS) manufacturing needed for phase 1 study completed**
  - Full-scale (1500L) batch of GMP DS manufactured with good yield and analytical methods and specifications suitable to support intravitreal administration.
- **Pre-IND meeting completed – providing clarity on path to IND**
- **Completing drug product (DP) manufacture and toxicology studies to potentially enable IND clearance in 2025**

# IVT Injected Drugs for Treatment of GA Are Potential Blockbusters

**5** million people worldwide have GA

**>1** million people in the U.S. are living with GA<sup>1-3</sup>



**Market cap \$3.3 billion**  
*as of Oct 10, 2024*

**Astellas acquisition for \$5.9 billion**  
*as of Jul 11, 2023*

The GA treatment market is expected to have CAGR of 7%+ and may exceed \$36 billion USD by 2032

## Value creation

- GA is a blockbuster market with significant unmet needs that PAS-nomacopan may address
- PAS-nomacopan GA program value and likelihood of partnering may increase significantly if IND clearance is received in 2025 and if subsequent clinical studies can be successfully completed

1. CDC <https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html>

2. AMDF Geographic Atrophy | American Macular Degeneration Foundation. <https://www.macular.org/about-macular-degeneration/geographic-atrophy>

3. Bakri et. al. 2023 Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system – PMC. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10408405/>

# *Nomacopan*

- *Phase 3-ready*
- *Efficacy and safety validated in PNH*

# *PHP-303*

- *5<sup>th</sup> generation inhibitor selective for bioactive form of neutrophil elastase*
- *In phase 1 multiple ascending study, 5-40 mg 1x daily PHP-303 regimen achieved >90% neutrophil elastase inhibition with largely grade 1 AEs*

Available for  
licensing/strategic  
partnership

# Nomacopan and PHP-303 Are Phase 2 and 3-Ready Clinical Assets Available for Licensing and Strategic Partnership

## Summary of nomacopan opportunity

- Phase 3-ready
- Recombinant compact globular (16.7kDa) protein
- Administered by subcutaneous injection for systemic indications
- Robust manufacturing process in bacteria at 1500L scale
- Clinical data (phase 1, 2 and 3) from 76 patients and healthy volunteers shows drug well tolerated
- Cumulative total human exposure 35 years
- Clinical efficacy demonstrated in **paroxysmal nocturnal hemoglobinuria (PNH)** and supported in **bullous pemphigoid (BP)**

## Summary of PHP-303 opportunity

- Phase 2-ready program
- 5<sup>th</sup> generation small molecule inhibitor of neutrophil elastase (NE)
- Administered oral once daily tablet
- Robust manufacturing process developed by Bayer
- Clinical phase 1 data from 60 healthy volunteers shows drug well tolerated and exhibits highly effective dose dependent inhibition of NE
- Phase 2 EU CTAs and protocols approved for PHP-303 trial in **Alpha-1 antitrypsin disease (AATD)** of the lung

### Value creation

- Clinical programs with significant commercial potential offers near-term BD potential



# Akari Therapeutics Is a Multi-Faceted Biotech Company



Diverse pipeline provides potential for multiple shots on goal



Lead assets in areas of high unmet medical need provide multi-billion-dollar market opportunities in oncology and geographic atrophy



Lead programs leverage unique mechanisms of action backed by robust preclinical data sets that point to potential clinical benefit



Merger brings end-to-end capabilities with a combined management team and board that brings proven track record of value creation in life sciences

*Supplementary  
Slides*

# *Nomacopan*

- *Phase 3-ready*
- *Efficacy and safety validated in PNH*

# *PHP-303*

- *5<sup>th</sup> generation inhibitor selective for bioactive form of neutrophil elastase*
- *In phase 1 multiple ascending study, 5-40 mg 1x daily PHP-303 regimen achieved >90% neutrophil elastase inhibition with largely grade 1 AEs*


Available for  
licensing/strategic  
partnership

# Nomacopan Is a Novel Bispecific Recombinant Protein


## Summary of nomacopan's properties

- Phase 3-ready
- Recombinant compact globular (16.7kDa) protein
- Administered by subcutaneous injection for systemic indications
- Robust manufacturing process in bacteria at 1500L scale
- Clinical data (phase 1, 2 and 3) from 76 patients and healthy volunteers shows drug well-tolerated
- Cumulative total human exposure 35 years
- Clinical efficacy demonstrated in **paroxysmal nocturnal hemoglobinuria (PNH)** and supported in **bullous pemphigoid (BP)**

Detailed understanding of C5 and LTB4 binding that is relevant to both nomacopan and PAS-nomacopan



High resolution structure of nomacopan (blue) bound to human **complement C5**<sup>1</sup>



High resolution structure of nomacopan capture of **LTB4** (yellow)<sup>2</sup>

# Potential Paths Forward for Monetization of Nomacopan Asset

## Partner or license nomacopan for:

A) An acute treatment indication such as trauma or traumatic brain injury using current formulation

B) Indication such as PNH for ROW (*i.e.* ex US/EU/Japan) using current formulation

- Leverage existing PNH data e.g. by reinitiating AK580 phase 3 trial and long-term safety trial AK581
- Price annual cost per patient highly competitively to encourage widest possible use
- Design trials to show that LTB4 inhibition has benefit in PNH in addition to C5 inhibition e.g. downregulates prothrombotic biomarkers
- Post approval for complement treatment naïve patients test if risk of thrombotic event lower on nomacopan than on complement only inhibitors

C) Develop slow-release formulation for clinical testing in either any disease currently treated with complement C5 inhibitors (lower risk approach) OR other chronic indications mediated by complement and/or LTB4

- List of diseases currently treated by inhibition of C5 activation includes PNH, myasthenia gravis (MG), atypical hemolytic uremic syndrome (aHUS) and neuromyelitis optica (NMO)
- Ensure highly competitive pricing/low annual cost per patient to encourage widest possible use
- Design trials to show that LTB4 inhibition has benefit in addition to C5 inhibition

# PHP-303

- *5<sup>th</sup> generation inhibitor selective for bioactive form of neutrophil elastase*
- *In Ph1 multiple ascending study, 5-40 mg 1x daily PHP-303 regimen achieved >90% neutrophil elastase inhibition with largely grade 1 AEs*

Available for  
licensing/strategic  
partnership

# PHP-303 Is a Potentially Best-in-Class Neutrophil Elastase Inhibitor (NEI) for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)



## Next Generation NEI

- PHP-303 is a small molecule, **oral QD**, reversible and highly selective NEI potentially addressing shortfalls of previous therapies
- PHP-303 can be an ideal solution for disease conditions where NE imbalance is an important contributor to disease




## PHP-303 Addresses the Unmet Medical Need in AATD

- Demonstrated dose-dependent NE Inhibition with largely grade 1 AEs in phase 1 clinical trials
- NE likely important determinant in AATD progression (chronic inflammatory imbalance); PHP-303 inhibits bioactive form of the enzyme
- Orphan disease status likely in US and EU
- Untapped potential with large delayed and/or misdiagnosed population
- Cost-effective alternative to current treatments

### Value creation

- Phase 2-ready program and asset with significant commercial potential offers near-term BD potential

# Dose-Dependent Inhibition of NE Activity by PHP-303 in Phase 1 Multiple Ascending Dose Study



An opportunity to develop a phase 1 derisked asset in an area of unmet medical need

- Sustained, dose-dependent suppression NE activity
- ~90% inhibition of NE activity by doses >5mg QD
- PHP-303 well-tolerated with largely grade 1 toxicities
- Phase 2 EU CTAs and protocols approved for PHP-303
- FDA has accepted A $\alpha$ -Val 360 and isodesmosine/desmosine as surrogate biomarkers for lung damage for alvelestat (competitor NEI) program
- Orphan disease potential for additional period of exclusivity
- Supported by grant from Alpha-1 project advocacy group